Chen Jie, Ma Na, Chen Bo, Huang Yin, Li Jinze, Li Jin, Chen Zeyu, Wang Puze, Ran Biao, Yang Jiahao, Bai Jingxing, Ning Shu, Ai Jianzhong, Wei Qiang, Liu Liangren, Cao Dehong
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Pediatrics, West China Second University Hospital, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu 610041, China.
Crit Rev Oncol Hematol. 2025 Mar;207:104604. doi: 10.1016/j.critrevonc.2024.104604. Epub 2024 Dec 26.
In recent years, cancer immunotherapy has received widespread attention due to significant tumor clearance in some malignancies. Various immunotherapy approaches, including vaccines, immune checkpoint inhibitors, oncolytic virotherapy, bispecific T cell engagers, and adoptive T cell transfer, have completed or are undergoing clinical trials for prostate cancer. Despite immune checkpoint blockade's extraordinary effectiveness in treating a variety of cancers, targeted prostate cancer treatment using the immune system is still in its infancy. Multiple factors including the heterogeneity of prostate cancer, the cold tumor microenvironment, and a low level of neoantigens, contribute to the poor immunotherapy response. Significant effort is being devoted to improving immune-based prostate cancer therapy. Recently, several key discoveries demonstrate that prostate cancer immunotherapy agents may be used to promise better prognosis for patients as part of combination strategies with other agents targeting tumor-associated immune mechanism of resistance. Here, this review comprehensively examines the recent advancements in immunotherapy for prostate cancer, exploring its potential synergistic effects when combined with other treatment modalities to enhance clinical efficacy.
近年来，癌症免疫疗法因在某些恶性肿瘤中能显著清除肿瘤而受到广泛关注。包括疫苗、免疫检查点抑制剂、溶瘤病毒疗法、双特异性T细胞衔接器和过继性T细胞转移在内的各种免疫疗法，已完成或正在进行前列腺癌的临床试验。尽管免疫检查点阻断在治疗多种癌症方面具有非凡的效果，但利用免疫系统靶向治疗前列腺癌仍处于起步阶段。包括前列腺癌的异质性、冷肿瘤微环境和新抗原水平低等多种因素，导致免疫治疗反应不佳。人们正在投入大量精力来改进基于免疫的前列腺癌治疗方法。最近，一些关键发现表明，前列腺癌免疫治疗药物作为与其他针对肿瘤相关免疫抵抗机制的药物联合策略的一部分，可能为患者带来更好的预后。在此，本综述全面审视了前列腺癌免疫治疗的最新进展，探讨了其与其他治疗方式联合时潜在的协同效应，以提高临床疗效。
